Cannabis News

Bipartisan Senators Push To Delay Federal Hemp THC Product Ban As Lawmakers Consider Regulatory Alternatives To Prohibition

Published

3 months ago

January 16, 2026

admin

A bipartisan group of senators is pushing to give the hemp industry two more years before the federal ban on THC products takes effect, which activists hope will better position them to negotiate a broader compromise with lawmakers.

After President Donald Trump signed a spending bill last year with provisions that would have wiped out a prominent sector of the hemp economy, businesses and advocates quickly called for at least a delay in its implementation. Currently, the law will enter into force in November.

Now, Senators Amy Klobuchar (D-MN), Rand Paul (R-KY) and Jeff Merkley (D-OR) have introduced new legislation that would push that timeline back another two years, giving hemp interests more time to say the policy would significantly harm the industry, which was legalized in Trump’s first term under the 2018 Farm Bill.

The measureEntitled the Hemp Planting Provision Act, it simply states: “Section 781 of the Appropriations Act of 2026 of the Agriculture, Rural Development, Food and Drug Administration, and Related Agencies (7 USC 1639o note; Public Law 119-37) is amended by striking “365 days” and inserting “365 years” in the subject matter before paragraph (1).

Rep. Jim Baird (R-IN) and bipartisan sponsor introduced similar legislation in the House to delay the hemp ban earlier this week.

House Oversight and Government Reform Committee Chairman James Comer (R-KY), who is sponsoring the proposal, appeared at a press conference on Thursday. farmers concerned about the impact of the federal hemp ban in their businesses.

what’s the point Four out of five marijuana users say they oppose the recriminalization of THC hemp products According to the spending bill Trump signed in November. However, it should be noted that this survey was conducted a few weeks before the cannabis rescheduling order and measures to protect access to full-spectrum CBD.

Trump signed an executive order last month directing the attorney general to change marijuana from Schedule I to Schedule III of the Controlled Substances Act (CSA).

Part of that announcement also has implications for the upcoming hemp law. The president’s order also asked Congress consider updating the definition of hemp to ensure that full-spectrum CBD is available to patients.

Another redefinition of hemp would be part of a novel proposal allow Medicare recipients to access non-toxic CBD that would be covered under the federal health care plan.

To make this happen, the Centers for Medicare and Medicaid Services (CMS) will “enable a model that will allow certain CMS beneficiaries to benefit from receiving CBD at no cost on the basis of a physician’s recommendation,” a White House official announced in a briefing. Marihuana Moment first reported the leaked details ahead of the signing ceremony.

Trump appeared to support a more flexible CBD policy last summer shared a video calling for that exact reform while promoting the health benefits of cannabidiolespecially for the elderly.

Meanwhile, it would make way for a recently introduced bill in the Republican-led Congress stop implementing the hemp ban under established credit legislation.

Hemp companies and industry groups have warned about the potential ramifications of the ban, but despite states in support of cannabis rights and a recent social media post extolling the benefits of CBD, Trump signed the underlying spending measure into law without endorsing the hemp provisions.

GOP political operative Roger Stone recently said it was Trump effectively “forced” Republican lawmakers to sign the spending bill with language to ban hemp THC.

However, a White House spokesman said before signing the bill Trump was particularly supportive of the ban’s language.

The Democratic governor of Kentucky said that the hemp industry is an “important” part of the economy that deserves to be regulated at the state level—instead of being banned federally, as Congress has done—.

Additionally, a leading veterans organization is alerting Congressional leaders to the recently passed blanket ban on consumable hemp products. could inadvertently “close the door” on critical inquiry.

—
It’s Marijuana Time tracking hundreds of cannabis, psychedelic and drug policy bills in state legislatures and Congress this year. Patreon supporters by pledging at least $25/month, you’ll get access to our interactive maps, charts, and audio calendars so you never miss a development.

Learn more about our marijuana bill tracking and become a Patreon supporter to gain access
—

Since 2018, cannabis products have been considered legal hemp if they contain less than 0.3 percent delta-9 THC by dry weight.

The new legislation specifies that, within a year of taking effect, the weight will be applied to total THC—including delta-8 and other isomers. Also, “as tetrahydrocannabinol (or any other marketed cannabinoid) with similar effects in humans or animals (as determined by the Secretary of Health and Human Services).”

The new definition of legal hemp will also prohibit “any hemp-derived cannabinoid intermediate product marketed or sold as an end product or directly to an end consumer for personal or household use” as well as products containing cannabinoids that are synthesized or manufactured outside of the cannabis plant or that are unable to produce it naturally.

Legal hemp products will be limited to a total of 0.4 milligrams of total THC or any other cannabinoid with similar effects per container.

Within 90 days of the bill’s passage, the Food and Drug Administration (FDA) and other agencies must “publish a list of all cannabinoids known to the FDA to be naturally produced by a Cannabis sativa L. plant, as reflected in the peer-reviewed literature,” which include “all tetrahydrocannabinol classes known” in natural plants and “known cannabinoids.” Cannabinoids that have or are marketed as having effects similar to cannabinoids of the tetrahydrocannabinol class.”

The language differs slightly from provisions in legislation advanced out of the House and Senate Appropriations panels, which would have banned products with “quantifiable” amounts of THC, to be determined by the HHS secretary and the agriculture secretary.

Read the full text of the Senate bill invoice below:

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Cannabis News

Cannabis growth facility eyes new spot for growth facility near Crisfield

Published

2 hours ago

May 1, 2026

admin

The Somerset County Board of Zoning Appeals approved another special exception for a cannabis-growing facility after negotiations to purchase a previous location failed to reach an agreement.

Trilogy Group LLC was granted a license to grow by the Maryland Cannabis Association, with the condition that the business be operational by July 2026. Trilogy Group wants to operate on the county-owned, undeveloped industrial site on Revell’s Neck Road in Westover. However, this project time frame does not coincide with the license term.

In September 2025, the producer was approved for a special exception for a facility at 4630 Crisfield Highway. The existing building houses Jed’s Auto Refinishing, which would be renovated to accommodate the growing operations. When the sale of that property ultimately failed, Trilogy Group purchased the land at 4381 Crisfield Highway and obtained another special exemption.

Jesse Drewer, Somerset’s Director of Technical and Community Services, said: “They looked for a site they already owned before coming to us and working through the process. “They are landlords and developers all in one.”

Cannabis News

Trump’s New Surgeon General Pick Said Using Marijuana Can Give You ‘Man Boobs’

Published

2 hours ago

May 1, 2026

admin

President Donald Trump’s new surgeon general nominee has raised concerns about marijuana, at one point saying its use is linked to the development of large breasts, or “man boobs,” in men. However, he also admitted that medical cannabis has “potential benefits”.

Trump announced Thursday that he would tap Nicole Saphier, who is now the director of breast imaging at Memorial Sloan Kettering, to be the surgeon general of the United States.

Saphier has repeatedly discussed what he sees as the dangers of marijuana use, and has been more open to the potential benefits of its non-intoxicating ingredient CBD.

“There is a common misconception that marijuana is safer than alcohol and other drugs,” he wrote on Fox News in 2019. “As a doctor I know that marijuana is not harmless and can have serious adverse effects on the health of users.”

“And as a mother of three (one in college), I’m concerned that legalizing the drug for adults sends a clear message to kids that they can get pot without negative health effects,” she said.

Saphier went on to criticize the 2020 Democratic presidential candidates who supported marijuana reform, saying it’s “politically a popular cause, especially among young voters.”

“These candidates are more interested in how legalization of pot will affect their electoral prospects than how legalization will affect public health,” he said. he wrote.

Among the health concerns he has raised is that cannabis use is “directly linked” to “man boobs”.

“Physically, we know that marijuana is directly linked to respiratory problems (if smoked), cardiovascular disease, and gynecomastia (“man nipples”). As a breast radiologist, the first question I ask men when they come in for breast augmentation is whether they currently smoke marijuana or have smoked it in the past. Often, the answer is “yes.”

Trump’s appointment of Saphier comes just as his administration is moving forward with federal rescheduling of marijuana.

Although the surgeon general has no formal involvement in the drug program, which is administered by the Department of Justice and the Department of Health and Human Services, the position is seen as “America’s doctor” and plays a role in addressing health issues on behalf of the government.

In a podcast earlier this year, Saphier admitted that there are “potential benefits” to medical cannabis.

“Of course, there is evidence supporting cannabinoids for chemotherapy-induced nausea, certain seizure disorders, chronic pain syndromes, multiple sclerosis,” he said. “But that’s very different than, you know, the general normalization of high-potency recreational cannabis on a daily basis, especially in developing brains, which doesn’t happen until age 25.”

In the same podcast, he said that he personally “doesn’t like” and has “never tried” cannabis.

“I think CBD products are probably significantly less harmful if they don’t have THC. I’m not a fan of THC,” Saphier. he said. “I think if people are trying to get away from alcohol and want to take low doses of CBD, not inhale it, not smoke it, I’m sure it’s probably less risky than some of the other things out there.”

“Let’s be honest, today’s cannabis is not your parents’ marijuana. The potency of THC has increased dramatically over the last two decades. High-concentrate products, vapes, dabs, edibles, what the kids are doing these days, I don’t even know.”

In another interview focused on concerns about cannabis use by pregnant women, Saphier he said “As we continue to legalize marijuana, people are equating that to, ‘it has to be safe.'”

In a separate interview, he suggested that the legalization of cannabis is increasing its use among young people, which he said increases rates of addiction and psychosis.

“One in six children who try it, becomes addicted. Cannabis use in children, the risk of psychosis is four times higher,” he said. “What have we done? Legalize. Normalize.”

Trump’s predecessor, now retired Candidate Casey Means discussed his “significant experiences” with psychedelics beforehand Saying that marijuana “can greatly decrease your ability to generate good energy.”

Means himself said during a confirmation hearing in February he would not advise Americans to experiment with psychedelics as he has donebut noted that there is “exciting” research indicating that substances such as psilocybin can effectively treat serious mental health conditions.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Cannabis News

Missouri cannabis growers file class action against Good Day Farm

Published

1 day ago

April 30, 2026

admin

CPC of Missouri-Smithville, LLC and GF Saint Mary LLC, licensed cannabis growers and manufacturers in Missouri, filed a lawsuit in the Circuit Court of Jackson County on behalf of independent wholesalers, alleging that Good Day Farm (GDF) and its network of conspiring companies and investors were harmed by an intentional, coordinated and unconstitutional scheme. The complaint alleges that the “GDF Cartel” illegally controls or manages the state’s share of dispensary licenses and uses that market power to manipulate Missouri’s $1.52 billion cannabis market for its own profit.

GDF and its co-conspirators allegedly built the cartel by arranging for third parties to invest in limited liability companies (LLCs) that then acquire additional dispensaries, cultivation and processing facilities, all of which are owned, operated or controlled by GDF. The result: The alleged cartel exercises effective control over at least 61 dispensaries, nearly triple the 22 allowed by the Missouri Constitution, with more than 10% of dispensary licenses “under substantially common control, ownership or management.” With 224 dispensaries currently licensed statewide, the alleged GDF Cartel controls more than one in four dispensary licenses in Missouri. But its influence is even greater, with alleged Cartel dispensaries accounting for more than 40% of wholesale cannabis in the state, giving it significant — and illegal — influence over all independent growers and manufacturers forced to sell through its network.

To avoid the Missouri Constitution’s 10% licensing limit and avoid regulatory oversight, the alleged cartel operates under five different brand names:

Good Day Farm (21 dispensaries),
CODES (20 dispensaries),
Green light (10 dispensaries),
Fresh Karma (6 dispensaries), and
3 Fifteen Primo (4 medications).

But they’re all part of a single, coordinated operation, the complaint says.

Purchase cannabis products from non-Cartel wholesalers at artificially depressed prices;
They supply their 61 dispensaries with the same products—mainly those produced by Cartel growers—significantly excluding products from independent wholesalers;
Force independent drug wholesalers to purchase the Cartel’s finished products as a condition for their wholesale products to be placed on the Cartel’s drug store shelves; and
Boycott non-cartel wholesalers who refuse to agree to anti-cartel demands.

Bob Hoffman, one of the attorneys leading the case, said: “The GDF Cartel is removing competition from the wholesale cannabis market and enriching itself with illegal profits through a counterproductive, clandestine business conspiracy. Missouri growers and manufacturers have been suffering under this scheme for a long time; many of them know something is wrong, but we don’t realize how the cartel has manipulated the market through this manipulation framework. Missourians to approve recreational cannabis in 2022 They voted for a fair and competitive market. Missouri licensed cannabis businesses that have suffered these practices should join us because they may be entitled to substantial damages.”

The complaint alleges the financial toll the Cartel has taken: Since the Cartel began illegal price-fixing, it has used its collective market power to lower wholesale prices by more than 20%, and continues to squeeze wholesalers and threaten the viability of their operations.

The unconstitutional complaint alleges that GDF knew its plan to build cartels could create legal risks for the company under the Constitution’s 10% licensing limit. The complaint quotes from a document provided by GDF to potential investors: “There can be no assurance that the Missouri Department of Cannabis Regulation will not dispute the number of marijuana dispensaries operated or supervised by the operator or its affiliates…”.

This action is brought on behalf of a putative class that includes all licensed independent wholesalers in Missouri that are not members of the alleged GDF Cartel for purposes of injunctive relief. Wholesalers who believe they have been financially harmed by the alleged Cartel’s practices should join the case because they may be entitled to substantial damages. The putative class is represented by the law firms of Feuerstein Kulick LLP and Bryan Cave Leighton Paisner LLP.

Source: Feuerstein Kulick LLP and Bryan Cave Leighton Paisner LLP